Replies to post #143356 on Biotech Values

[DewDiligence]

ABT’s Humira PR’s from EULAR…

• Phase-3 data in active non-radiographic axial spondyloarthritis (a new indication for the TNF-a class) from ABILITY-1 study:
http://finance.yahoo.com/news/abbott-presents-phase-3-study-050500557.html

• Phase-3 data in active peripheral spondyloarthritis from ABILITY-2 study:
http://finance.yahoo.com/news/abbott-presents-phase-3-study-120000711.html

• 10-year open-label-extension data for patients with moderate-to-severe RA:
http://finance.yahoo.com/news/abbott-announces-10-data-evaluating-051000897.html